Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab…(VERU-111) | Phase 2 | withdrawn | Aug 17, 2021 | Veru Inc. | Decided to halt and will potentially reopen in the future. | Other (stated, no rule matched) |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | Phase 2 | withdrawn | Apr 9, 2019 | Louisiana State University Health Sciences Center in New Orleans | Dr. Marshall left UMC and LSU Health Sciences Center. | Other (stated, no rule matched) |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | N/A | withdrawn | Oct 29, 2021 | Roswell Park Cancer Institute | PI left institute-no accruals | Investigator |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for… | Phase 1 / Phase 2 | terminated | Sep 15, 2016 | PharmaEngine | bussiness reason | Other (stated, no rule matched) |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer…(PANTHEON) | Phase 2 | terminated | Nov 6, 2017 | AIO-Studien-gGmbH | slow recruitment | Enrollment / accrual |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast… | Phase 1 | terminated | Mar 5, 2020 | National Cancer Institute (NCI) | One participant was accrued, and the study was stopped due to new safety data from the company for… | Safety / toxicity |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | Phase 2 | terminated | Dec 4, 2020 | Zhejiang University | The treatment efficacy was not satisfactory. | Efficacy / futility |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | Phase 2 | terminated | Jul 20, 2020 | SC Liver Research Consortium, LLC | Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity… | Safety / toxicity |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With… | Phase 2 | terminated | Feb 13, 2017 | National Cancer Institute (NCI) | Terminated after an unplanned interim efficacy analysis. | Efficacy / futility |
| NCT04672876 | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With… | Phase 2 | withdrawn | Dec 17, 2020 | University of Chicago | Trial funding no longer available. | Funding |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of…(HiQuality) | Phase 3 | terminated | Jul 6, 2011 | Merit Medical Systems, Inc. | The clinical study was terminated due to the inability to meet target enrollment. | Enrollment / accrual |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic… | Phase 1 / Phase 2 | terminated | Mar 6, 2017 | Transgene | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab… | Other (stated, no rule matched) |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic… | Phase 2 | withdrawn | May 6, 2021 | 4SC AG | Refocusing of sponsor's clinical development program. No safety concern or change of the… | Safety / toxicity |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for… | Phase 2 | terminated | May 13, 2014 | Dana-Farber Cancer Institute | no enough patients | Other (stated, no rule matched) |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT02438995 | Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation… | Phase 1 | terminated | May 8, 2015 | Northwell Health | Low enrollment | Enrollment / accrual |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in…(DESPARTH) | Phase 1 | terminated | Dec 1, 2014 | University Hospital, Ghent | slow recruitment of patients | Enrollment / accrual |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer… | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Immune System Key Ltd | Patients were screened but not enrolled | Enrollment / accrual |
| NCT03408652 | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in…(MOSCAR) | Phase 3 | terminated | Jan 24, 2018 | Centre Leon Berard | lack of recruitment | Enrollment / accrual |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San…(HCC) | N/A | terminated | Jun 10, 2010 | Loma Linda University | due to low enrollment | Enrollment / accrual |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin…(SHERLOC) | Phase 2 | terminated | Mar 12, 2015 | Elevation Oncology | Based on the preliminary results seen during interim analysis, which were confirmed in the final… | Efficacy / futility |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT01957514 | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative…(ITOMIC) | — | terminated | Oct 8, 2013 | University of Washington | Terminated due to loss of funding. | Funding |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | Phase 2 | terminated | Mar 31, 2015 | Swiss Cancer Institute | The trial was prematurely terminated as of 22.07.2021 as per SAKK board decision board decision… | Other (stated, no rule matched) |
| NCT04311047 | Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma…(NANO-PANC) | N/A | terminated | Mar 17, 2020 | Radboud University Medical Center | We decided to stop inclusions and start analysis after 26 inclusions. | Other (stated, no rule matched) |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2…(PREDIXIIHER2) | Phase 2 | terminated | Mar 28, 2019 | Renske Altena | Security and effect data from another ongoing study. | Other (stated, no rule matched) |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC… | Phase 3 | terminated | Nov 2, 2016 | Pfizer | The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has… | Efficacy / futility |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic… | Phase 2 | terminated | Apr 14, 2017 | Weill Medical College of Cornell University | Lack of accrual | Enrollment / accrual |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And…(AtezoVax) | Phase 2 | withdrawn | Jul 15, 2019 | University of Utah | funding source withdrawn | Funding |
| NCT02885649 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | Early Phase 1 | terminated | Aug 31, 2016 | Rutgers, The State University of New Jersey | Funding unavailable | Funding |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or…(NIVOSWITCH) | Phase 2 | terminated | Nov 9, 2016 | AIO-Studien-gGmbH | not stated | Not stated |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive… | Phase 2 | terminated | Dec 7, 2016 | Sanofi | Study discontinued considering the limited clinical benefit combined with a higher than expected… | Other (stated, no rule matched) |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | Phase 1 | terminated | Jan 2, 2018 | Ascentage Pharma Group Inc. | The company adjusts strategy. | Sponsor / business decision |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple…(PANDoRA) | Phase 2 | withdrawn | Mar 13, 2019 | Cedars-Sinai Medical Center | lack of funding | Funding |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to… | — | withdrawn | Dec 23, 2020 | TScan Therapeutics, Inc. | Lack of patient samples | Other (stated, no rule matched) |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients… | Phase 1 | withdrawn | Jan 16, 2012 | Gilead Sciences | no subjects enrolled | Enrollment / accrual |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial… | Early Phase 1 | withdrawn | Oct 23, 2013 | University of Arkansas | Study has been open for 8 years with no enrollment. Procedures in 2013 protocol are outdated.… | Enrollment / accrual |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With… | Phase 2 | withdrawn | Jun 12, 2014 | Gilead Sciences | FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 8, 2022source: clinicaltrials